Literature DB >> 11303808

Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia.

G Menashe1, A Borer, P Yagupsky, N Peled, J Gilad, D Fraser, K Riesenberg, F Schlaeffer.   

Abstract

During an 8-month period, 55 episodes of nosocomial bacteremia caused by Enterobacteriaceae species were identified in a tertiary medical center, of which 26 (47%) were caused by extended-spectrum beta lactamase (ESBL)-producing organisms. ESBL production was associated with resistance to aminoglycosides, fluoroquinolones, tetracycline and co-trimoxazole compared with non-ESBL-producing organisms (p < 0.01). By multivariate analysis, infection with ESBL-producing organisms was associated with previous antibiotic therapy and central venous catheter insertion and mortality was associated with heart failure, malignancy and a prolonged hospital stay. Nineteen (73%) patients infected with ESBL-producing organisms received adequate empirical antibiotic therapy and all 26 received adequate definitive therapy. The in-hospital mortality rate did not differ between patients infected with ESBL producers and those infected by non-ESBL-producing Enterobacteriaceae species [13/26 (50%) and 11/29 (38%), respectively] (p > 0.5).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303808     DOI: 10.1080/00365540151060806

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  20 in total

1.  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Authors:  Mario Tumbarello; Maurizio Sanguinetti; Eva Montuori; Enrico M Trecarichi; Brunella Posteraro; Barbara Fiori; Rita Citton; Tiziana D'Inzeo; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

2.  Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.

Authors:  Mario Tumbarello; Teresa Spanu; Maurizio Sanguinetti; Rita Citton; Eva Montuori; Fiammetta Leone; Giovanni Fadda; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism.

Authors:  Katherine E Goodman; Justin Lessler; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Jennifer H Han; Aaron M Milstone; Colin J Massey; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2016-06-28       Impact factor: 9.079

4.  Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Authors:  Pranita D Tamma; Jennifer H Han; Clare Rock; Anthony D Harris; Ebbing Lautenbach; Alice J Hsu; Edina Avdic; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

5.  Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.

Authors:  Andrea Endimiani; Francesco Luzzaro; Gioconda Brigante; Mariagrazia Perilli; Gianluigi Lombardi; Gianfranco Amicosante; Gian Maria Rossolini; Antonio Toniolo
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Evaluation of the current National Committee for Clinical Laboratory Standards guidelines for screening and confirming extended-spectrum beta-lactamase production in isolates of Escherichia coli and Klebsiella species from bacteremic patients.

Authors:  O T Katz; N Peled; P Yagupsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-08       Impact factor: 3.267

7.  Clinical epidemiology and outcomes of biliary tract infections caused by Klebsiella pneumoniae.

Authors:  Lanyu Li; Changqing Zhu; Huan Huang
Journal:  Ann Transl Med       Date:  2019-07

8.  Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients.

Authors:  Hossam M Ashour; Amany El-Sharif
Journal:  J Transl Med       Date:  2009-02-19       Impact factor: 5.531

9.  Reference group choice and antibiotic resistance outcomes.

Authors:  Keith S Kaye; John J Engemann; Essy Mozaffari; Yehuda Carmeli
Journal:  Emerg Infect Dis       Date:  2004-06       Impact factor: 6.883

10.  Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence.

Authors:  Alexandre R Marra; Sérgio B Wey; Adauto Castelo; Ana Cristina Gales; Ruy Guilherme R Cal; José R do Carmo Filho; Michael B Edmond; Carlos Alberto P Pereira
Journal:  BMC Infect Dis       Date:  2006-02-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.